糠酸莫米松鼻窦植入剂治疗复发性鼻息肉的3期试验
这项随机、假手术对照、双盲3期试验纳入300例难治性慢性鼻窦炎伴鼻息肉且为再次手术候选者的成人,按2:1随机接受双侧鼻窦植入剂(约90天释放1350 μg糠酸莫米松)或假手术,所有患者均使用糠酸莫米松鼻喷剂200 μg每日一次。结果显示植入剂组鼻塞/充血评分和双侧息肉分级较对照组显著改善,且需再次鼻窦手术的患者比例降低61%。
要点
- 糠酸莫米松鼻窦植入剂可显著改善复发性鼻息肉患者的鼻塞和息肉分级。
- 植入剂使需再次鼻窦手术的患者比例降低61%。
- 植入剂组4/5预设次要终点显著优于对照,但面部疼痛/压力无差异。
核心结论
- 糠酸莫米松鼻窦植入剂在复发性鼻息肉患者中较假手术对照显著改善鼻塞/充血评分和双侧息肉分级。
- 植入剂使需要再次鼻窦手术的患者比例降低61%。
研究设计与样本
- 随机、假手术对照、双盲3期试验,纳入300例难治性慢性鼻窦炎伴鼻息肉且为再次手术候选者的成人。
- 患者按2:1随机接受诊室双侧放置2枚植入剂或假手术,所有患者使用糠酸莫米松鼻喷剂200 μg每日一次。
主要发现
- 植入剂组鼻塞/充血评分较对照组显著降低(p = 0.0074)。
- 植入剂组双侧息肉分级较对照组显著降低(p = 0.0073)。
- 第90天时,植入剂组在5个预设次要终点中的4个显著优于对照:仍需再次鼻窦手术的患者比例(p = 0.0004)、筛窦阻塞百分比(p = 0.0007)、鼻塞/充血(p = 0.0248)和嗅觉减退(p = 0.0470),但面部疼痛/压力无显著差异(p = 0.9130)。
- 1例患者发生与植入剂相关的严重不良事件(鼻出血)。
关键数值与推荐
- 植入剂在约90天内向筛窦黏膜直接释放1350 μg糠酸莫米松。
- 所有患者使用糠酸莫米松鼻喷剂200 μg每日一次。
- 共-primary终点为鼻塞/充血评分和双侧息肉分级较基线的变化,由独立小组基于集中盲法视频内镜审阅确定。
临床怎么用
- 对于复发性鼻息肉且为再次手术候选者的患者,糠酸莫米松鼻窦植入剂可作为减少手术需求的治疗选择。
- 植入剂在诊室双侧放置,需注意植入剂相关严重不良事件(如鼻出血)的监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Topical intranasal corticosteroid sprays (INCSs) are standard treatment for nasal polyps (NPs), but their efficacy is reduced by poor patient compliance and impaired access of drug to the sinus mucosa. A corticosteroid-eluting sinus implant was designed to address these limitations in patients with recurrent polyposis after sinus surgery by delivering 1350 μg of mometasone furoate (MF) directly to the ethmoid sinus mucosa over approximately 90 days. METHODS: A randomized, sham-controlled, double-blind trial was undertaken in 300 adults with refractory chronic rhinosinusitis with NPs (CRSwNP), who were candidates for repeat surgery. Eligible patients were randomized (2:1) and underwent in-office bilateral placement of 2 implants or a sham procedure. All patients used the MF INCS 200 μg once daily. Co-primary efficacy endpoints were the change from baseline in nasal obstruction/congestion score and bilateral polyp grade, as determined by an independent panel based on centralized, blinded videoendoscopy review. RESULTS: Patients treated with implants experienced significant reductions in both nasal obstruction/congestion score (p = 0.0074) and bilateral polyp grade (p = 0.0073) compared to controls. At day 90, implants were also associated with significant reductions in 4 of 5 prespecified secondary endpoints compared to control: proportion of patients still indicated for repeat sinus surgery (p = 0.0004), percent ethmoid sinus obstruction (p = 0.0007), nasal obstruction/congestion (p = 0.0248), and decreased sense of smell (p = 0.0470), but not facial pain/pressure (p = 0.9130). One patient experienced an implant-related serious adverse event (epistaxis). CONCLUSION: Significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that MF sinus implants may play an important role in management of recurrent NP.
引用
- Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol. 2018. PMID: 29350840. doi:10.1002/alr.22084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。